Cat. No. | Product name | CAS No. |
DC2060 |
CI994 (Tacedinaline)
Featured
CI994 (Tacedinaline) is an anti-cancer drug which inhibits HDAC1 with IC50 of 0.57 μM. |
112522-64-2 |
DC2099 |
cis-Diaminedichloroplatinum
Featured
Cisplatin is an inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. |
15663-27-1 |
DC11107 |
CKD-516
CKD-516 (Valecobulin, CKD516) is a potent beta-tubulin polymerization inhibitor with marked antitumor activity both in vitro and in vivo. |
1188371-47-2 |
DC9799 |
CNDAC
Featured
CNDAC is the active component of sapacitabine. |
135598-68-4 |
DC8651 |
CO-1686 hydrobromide
Featured
CO-1686 hydrobromide is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M (IC50=21 nM). |
1446700-26-0 |
DC7106 |
Rociletinib (CO-1686)
Featured
CO-1686 is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M(IC50=21 nM). |
1374640-70-6 |
DC10657 |
COTI-2
Featured
COTI-2 is a small molecule candidate anti-cancer drug which can convert mutant p53 to wild-type conformation. |
1039455-84-9 |
DC10527 |
Ciforadenant (CPI-444)
Featured
CPI-444 is an orally administered antagonist of the adenosine A2A receptor. It is designed to block the action of adenosine that is produced by tumors. |
1202402-40-1 |
DC5159 |
CP-868596 (Crenolanib)
Featured
Crenolanib (CP-868596) is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB |
670220-88-9 |
DC11642 |
Cridanimod sodium
Featured
Cridanimod sodium is a potent type I interferon (IFN) inducer that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route. |
58880-43-6 |
DC7544 |
CUDC-101
Featured
CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1. |
1012054-59-9 |
DC7111 |
CX-4945 (Silmitasertib)
Featured
CX-4945 (Silmitasertib) is a potent and selective ATP-competitive small molecule protein kinase CK2 inhibitor with a Ki and an IC50 of 0.38 and 1 nM for recombinant human CK2α, respectively. |
1009820-21-6 |
DC7810 |
CX-5461
Featured
CX-5461 is an inhibitor of rRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA, has no effect on Pol II, and possesses 250-to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation. |
1138549-36-6 |
DC7153 |
CX6258
Featured
CX-6258 is a potent, orally efficacious Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor with excellent biochemical potency and kinase selectivity. |
1202916-90-2 |
DC10775 |
Fadraciclib (CYC065)
Featured
CYC065 is an orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9) with potential antineoplastic and chemoprotective activities. |
1070790-89-4 |
DC9013 |
Cyclophosphamide
Featured
Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. |
50-18-0 |
DC3107 |
Momelotinib (CYT387,CYT-387)
Featured
CYT387 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC50 of 11 nM and 18 nM, respectively. |
1056634-68-4 |
DC5134 |
lexibulin (CYT997)
CYT997 is a potent microtubule polymerization inhibitor with IC50 of 10-100 nM in cancer cell lines. Phase 1/2. |
917111-44-5 |
DC4125 |
PHA-739358 (danusertib)
Featured
Danusertib (PHA-739358) is an Aurora inhibitor for Aurora A/B/C, Bcr-Abl, c-RET and FGFR with IC50 of 13 nM/79 nM/61 nM, 25 nM, 31 nM and 47 nM, respectively. |
827318-97-8 |
DC2100 |
Dasatinib (BMS-354825)
Featured
Dasatinib (BMS-354825, Sprycel) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.5 nM and 79 nM, respectively. |
302962-49-8 |
DC7069 |
Daunorubicin HCL
Featured
Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM. |
23541-50-6 |
DC5041 |
DCC-2036 (Rebastinib)
Featured
DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1/2. |
1020172-07-9 |